Popular Trials
Growth Hormone Releasing Hormone Analog
Tesamorelin for Non-alcoholic Fatty Liver Disease
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is investigating whether a drug called tesamorelin, which helps the body produce growth hormone, can reduce the amount of fat in the liver and improve liver inflammation in people with obesity and nonalcoholic fatty liver disease.
Hormone Therapy
Digoxin for Fatty Liver Disease
Recruiting0 awardsPhase 2
New Haven, Connecticut
"This trial aims to find a new treatment for a liver condition called NASH, which affects many Americans. Current treatment involves lifestyle changes like weight loss and managing other health conditions. There is a need for
Popular Filters
Trials for NAFLD Patients
Efinopegdutide for Nonalcoholic Steatohepatitis (NASH)
Recruiting0 awardsPhase 2
Hialeah, Florida
This trial is testing a new medicine called efinopegdutide to see if it can help people with a liver disease called non-alcoholic steatohepatitis (NASH). Researchers want to find out if this medicine can reduce the symptoms of NASH without making liver scarring worse. They are also checking how safe the medicine is and how well people can tolerate it.
LY3849891 for Non-alcoholic Fatty Liver Disease
Recruiting0 awardsPhase 1
Rialto, California
This trial is testing a new medication called LY3849891 in people with fatty liver disease who have a specific genetic variant. The study will check how the drug affects liver fat and how the body processes it using blood tests and imaging.
Trials for Non-alcoholic Fatty Liver Disease Patients
Efinopegdutide for Nonalcoholic Steatohepatitis (NASH)
Recruiting0 awardsPhase 2
Hialeah, Florida
This trial is testing a new medicine called efinopegdutide to see if it can help people with a liver disease called non-alcoholic steatohepatitis (NASH). Researchers want to find out if this medicine can reduce the symptoms of NASH without making liver scarring worse. They are also checking how safe the medicine is and how well people can tolerate it.
LY3849891 for Non-alcoholic Fatty Liver Disease
Recruiting0 awardsPhase 1
Rialto, California
This trial is testing a new medication called LY3849891 in people with fatty liver disease who have a specific genetic variant. The study will check how the drug affects liver fat and how the body processes it using blood tests and imaging.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.